APA (7th ed.) Citation

Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F., . . . Poveda, A. (2011). Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. Journal of clinical oncology, 29(15_suppl), 5046. https://doi.org/10.1200/jco.2011.29.15_suppl.5046

Chicago Style (17th ed.) Citation

Monk, B. J., et al. "Final Survival Results of the Randomized Phase III Study of Trabectedin with Pegylated Liposomal Doxorubicin (PLD) Versus PLD in Recurrent Ovarian Cancer." Journal of Clinical Oncology 29, no. 15_suppl (2011): 5046. https://doi.org/10.1200/jco.2011.29.15_suppl.5046.

MLA (9th ed.) Citation

Monk, B. J., et al. "Final Survival Results of the Randomized Phase III Study of Trabectedin with Pegylated Liposomal Doxorubicin (PLD) Versus PLD in Recurrent Ovarian Cancer." Journal of Clinical Oncology, vol. 29, no. 15_suppl, 2011, p. 5046, https://doi.org/10.1200/jco.2011.29.15_suppl.5046.